Product Information
POTASSIUM CL ER 8 MEQ TABLET is a generic product labeled by Strides Pharma Inc., priced at $0.1229 per EA under NDC 64380086006. Its NADAC has been published 390 times since Dec 5, 2018.
FDA first approved this application on Aug 31, 2018. Its Orange Book therapeutic-equivalence code is AB2 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
600 mg/1
Manufacturer
Strides Pharma Inc.NDC
64380086006
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
5/20/2026
Active Ingredients
POTASSIUM CHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA210733FDA Approved
8/31/2018
TE Code
AB2
On Market Since
11/19/2018
Pharmacological Classes
Price Statistics
The NADAC for POTASSIUM CL ER 8 MEQ TABLET has been published 390 times since Dec 5, 2018, and over the history we have for it it has declined 41.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1229 per EA |
|---|---|
| All-time high | $0.2399 (Jan 15, 2020) |
| All-time low | $0.1059 (Apr 17, 2024) |
| 52-week high | $0.1411 |
| 52-week low | $0.1196 |
| Median price | $0.1620 |
| Average price | $0.1679 |
| Largest weekly change | -39.3% (Apr 17, 2024) |
| Weeks tracked | 390 |
| Tracking since | Dec 5, 2018 |
1W
N/A
1M
N/A
3M
N/A
6M
-1.7%
1Y
-10.2%
3Y
-14.7%
5Y
-30.2%
All
-41.3%
Last surveyed May 20, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 16% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Strides Pharma Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Potassium Chloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Osmotic Laxative class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of POTASSIUM CL ER 8 MEQ TABLET?
The current National Average Drug Acquisition Cost (NADAC) for POTASSIUM CL ER 8 MEQ TABLET, manufactured by Strides Pharma Inc., is $0.1229 per EA (NDC 64380086006), effective May 20, 2026.
How has the price of POTASSIUM CL ER 8 MEQ TABLET changed over time?
Over the history we have for it, the NADAC for POTASSIUM CL ER 8 MEQ TABLET has declined 41.3%. It has been tracked across 390 weekly CMS publications since Dec 5, 2018.
What are the highest and lowest recorded NADAC prices for POTASSIUM CL ER 8 MEQ TABLET?
Since Dec 5, 2018, the NADAC for POTASSIUM CL ER 8 MEQ TABLET has ranged from a low of $0.1059 (Apr 17, 2024) to a high of $0.2399 (Jan 15, 2020), with a median of $0.1620 per EA.
Are there cheaper alternatives to POTASSIUM CL ER 8 MEQ TABLET?
Yes. 5 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, POTASSIUM CL ER 8 MEQ TABLET, is $0.1028 per EA — about 16% below POTASSIUM CL ER 8 MEQ TABLET.
Who manufactures POTASSIUM CL ER 8 MEQ TABLET?
POTASSIUM CL ER 8 MEQ TABLET (NDC 64380086006) is labeled by Strides Pharma Inc., and CMS classifies it as a generic product.